Press Release: Esperance : Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting

BATON ROUGE, La., June 1, 2015 /PRNewswire/ -- Esperance Pharmaceuticals Inc. today reported positive results from a Phase II trial of lead candidate EP-100 in ovarian cancer patients resistant to paclitaxel. EP-100 is a targeted membrane-disrupting peptide designed to seek and destroy...

Read full article »

Top Competitors or Alternatives

Looks like nobody has added any competitors for Esperancepharma yet.

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Hector Alila's photo - President & CEO of Esperancepharma

President & CEO

Hector Alila

CEO Approval Rating


Esperance is a clinical stage company, that develops targeted anticancer drugs. Read more